Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Comparative Effectiveness of Single Versus Dual Adjuvant Therapy After Breast-Conserving Surgery in Hormone Receptor-Positive Ductal Carcinoma In Situ: A Multicenter Retrospective Cohort Study.

Created on 14 Nov 2026

Authors

Yuqiang Huang, Xianqiang Du, Junjing Li, Debo Chen

Published in

Journal of clinical medicine. Volume 15. Issue 21. Nov 09, 2026. Epub Nov 09, 2026.

Abstract

Background/Objectives: To evaluate the comparative effectiveness of single versus dual adjuvant treatment strategies for hormone receptor-positive (HR+) ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS). Methods: This was a multicenter, retrospective study. We retrospectively identified 645 patients with HR+ DCIS who underwent BCS between 2009 and 2020 from the Shanghai Jiao Tong University Breast Cancer Database (SJTU-BCDB). Patients were stratified according to adjuvant treatment regimens: BCS alone, BCS combined with radiotherapy (BCS + RT), BCS combined with endocrine therapy (BCS + ET), and BCS combined with radiotherapy and endocrine therapy (BCS + RT + ET). The primary endpoint was recurrence-free survival (RFS). Multivariable Cox regression and inverse probability of treatment weighting (IPTW) analyses were performed to evaluate treatment associations with RFS outcomes. Results: The median follow-up was 74.0 months. In multivariable Cox regression, compared with BCS + RT + ET, neither BCS + RT (HR, 0.62; 95% CI, 0.12-3.13; p = 0.564) nor BCS + ET (HR, 1.49; 95% CI, 0.43-5.11; p = 0.525) showed a statistically significant difference in RFS. IPTW-adjusted analyses similarly showed no statistically significant differences between BCS + RT and BCS + RT + ET (HR, 0.28; 95% CI, 0.06-1.44; p = 0.128) or between BCS + ET and BCS + RT + ET (HR, 1.82; 95% CI, 0.49-6.82; p = 0.373). Conclusions: Among patients with HR+ DCIS undergoing BCS, no statistically significant difference in RFS was observed between dual-modality and single-modality adjuvant therapy. However, the limited number of events and wide confidence intervals limit the precision of estimates regarding the incremental benefit of combined RT and ET. Larger prospective studies with adequate statistical power are warranted to further define the comparative effectiveness of these treatment strategies.

PMID:
43030871
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement